

N.H. Kumar Baba, D. Ashok*, Boddu Ananda Rao, Sarasija Madderla and N.Y.S. Murthy

Microwave-assisted synthesis and biological evaluation of thiazole-substituted dibenzofurans

<https://doi.org/10.1515/hc-2017-0247>

Received December 1, 2017; accepted March 14, 2018; previously published online May 9, 2018

Abstract: New thiazole-substituted dibenzofurans **7a–j** were synthesized from dibenzofuran derivatives **5a–b** and substituted thiosemicarbazones **6a–h** under conventional and microwave irradiation conditions. The structures of all products were established on the basis of analytical and spectral data. The synthesized compounds were evaluated for their *in vitro* antibacterial activity against Gram-positive and Gram-negative strains. Compounds **7b**, **7d** and **7h** are active against *Bacillus subtilis* (+ve), and compound **7i** displays good activity against *Pseudomonas aeruginosa* (–ve) strain. Compounds **7a–j** were also evaluated for their *in vitro* antimycobacterial activity, and compound **7b** shows antimycobacterial activity against *Mycobacterium bovis* strain.

Keywords: antibacterial; antimycobacterial; benzofuran; microwave irradiation; thiazole.

Introduction

During the past decades, the synthesis of thiazoles and analogs has gained interest due to their broad range of biological and pharmaceutical properties, such as antibacterial [1–4], anti-human immunodeficiency virus type 1 (HIV-1) [5], antihypertensive [6], anti-inflammatory [7], antiviral [8, 9] and anticancer activities [10]. Thiosemicarbazones have also gained importance in medicinal chemistry [11, 12] and are being extensively used in the

synthesis of thiazoles [13]. In recent years, many thiazolyl hydrazone derivatives have been synthesized and screened for antimicrobial [14] and antimycobacterial [15] activities. Benzodifurans are also bioactive [16, 17]. In particular, benzo[*b*]furan derivatives substituted at the C-2 position show good biological activities [18, 19]. Microwave-assisted organic synthesis of heterocyclic compounds has become an effective technique for generating new heterocyclic scaffolds useful for drug discovery [20]. Currently, microwave irradiation methods, especially the synthesis of thiazolyl hydrazine derivatives via the condensation of α -bromoketones with thiosemicarbazones, have shown great promise as an attractive alternative to conventional methods. Inspired by the biological profile of thiazolyl hydrazine derivatives and in continuation of our previous work [21], we have focused our attention on the preparation of symmetrical thiazole and benzodifuran derivatives **7a–j**. These products were synthesized by conventional and microwave methods and investigated *in vitro* for antibacterial and antimycobacterial activities.

Results and discussion

Compounds **7a–j** were prepared from 2,4-diacetylresorcinol (**1**) which, in turn, was synthesized according to the literature procedure [22], as shown in Scheme 1. First, the starting material **1** was treated with two equivalents of a benzaldehyde in an aqueous solution of potassium hydroxide. The resulting bis-chalcones **2a–b** were then hydrogenated using 10% Pd/C in ethyl acetate. The products **3a–b** were treated with chloroacetone in acetone in the presence of potassium carbonate. Then, the products **4a–b** were brominated by pyridinium tribromide in acetic acid. The reaction of products **5a–b** with substituted thiosemicarbazones **6a–h** in ethanol under microwave irradiation afforded the desired final compounds **7a–j** in high yields (method B). The yields were lower for the same reactions conducted using the conventional heating method (method A). The structures of the synthesized compounds **3a,b**, **4a,b**, **5a,b** and **7a–j** were established by spectroscopic means [infrared (IR), proton nuclear magnetic resonance (^1H NMR), carbon-13 nuclear magnetic resonance (^{13}C NMR), mass spectrometry (MS)] and elemental analyses.


***Corresponding author: D. Ashok**, Green and Medicinal Chemistry Laboratory, Department of Chemistry, Osmania University, Hyderabad 500007, India, e-mail: ashokdou@gmail.com

N.H. Kumar Baba: Department of Chemistry, Jawaharlal Nehru Technological University, Hyderabad 500085, Telangana, India; and Chemveda Life Sciences India Pvt Ltd., I.D.A. Uppal, Hyderabad 500039, Telangana, India

Boddu Ananda Rao: Green and Medicinal Chemistry Laboratory, Department of Chemistry, Osmania University, Hyderabad 500007, India

Sarasija Madderla: Department of Chemistry, Satavahana University, Karimnagar 505001, Telangana, India

N.Y.S. Murthy: Department of Chemistry, Anurag Group of Institutions, Hyderabad 501301, Telangana, India



Scheme 1

Table 1 Antibacterial activity of compounds 7a–j.

Compound	Zone of inhibition after 24 h (mm)			
	Gram-positive bacteria		Gram-negative bacteria	
	<i>S. aureus</i> (MTCC 737)	<i>B. subtilis</i> (MTCC 441)	<i>E. coli</i> (MTCC 443)	<i>P. aeruginosa</i> (MTCC 741)
7a	8.5	11	4.5	6
7b	14	25	5.5	7
7c	4	7	5.5	7
7d	11	21	4.5	6
7e	6.5	12	2.5	2.5
7f	4.5	6	5.5	5
7g	7.5	10	4	6.5
7h	9	21	6	8
7i	5.5	8	9	11
7j	5.5	9	5.5	6
Norfloxacin	16	20		
Ofloxacin			18	10

The *in vitro* antimicrobial activities of compounds **7a–j** were investigated against four pathogenic micro-organisms, namely *Staphylococcus aureus* (MTCC 737), *Escherichia coli* (MTCC 443), *Bacillus subtilis* (MTCC 441) and *Pseudomonas aeruginosa* (MTCC 741) at a concentration of 100 µg/mL using norfloxacin and ofloxacin as standard drugs by the cup-plate agar diffusion method.

The results are presented in Table 1. As can be seen, compounds **7b**, **7d**, **7h** (inhibition zone >20 mm) show excellent growth inhibition against *B. subtilis* as compared to norfloxacin (20 mm). Compound **7i** is more potent than the standard (ofloxacin) against Gram-negative bacterial strain *P. aeruginosa*. The investigation of *in vitro* antimicrobial activity (Table 2) revealed that compounds

Table 2 Antimycobacterial activity of compounds 7a–j.

Compound	Zone of inhibition (mm)
	<i>M. bovis</i>
7a	15.1
7b	42.2
7c	19.5
7d	26.9
7e	27.8
7f	32.5
7g	16.9
7h	36.6
7i	10.9
7j	21.5
Isoniazid + rifampicin	40.0

7b and 7h are active compared to the standard mixture of isoniazid and rifampicin (Scheme 1).

Conclusions

New antibacterial and antimycobacterial inhibitors 7a–j were synthesized via symmetrical construction of a thiazole ring at each C-2 position of benzodifuran using both conventional and microwave irradiation methods. Compounds 7b, 7d, 7h show excellent growth inhibition against *B. subtilis* as compared to norfloxacin. In comparison to ofloxacin, compound 7i is highly effective against Gram-negative bacterial strain *P. aeruginosa*. Compound 7b shows excellent *in vitro* antimycobacterial activity.

Experimental

IR spectra were recorded on a Shimadzu FTIR-8400S spectrometer using KBr pellets. ¹H NMR spectra (300 MHz) and ¹³C NMR spectra (75 MHz) were acquired on a Bruker Avance 300 spectrometer in CDCl₃ or dimethyl sulfoxide-d₆ (DMSO-*d*₆) using tetramethylsilane (TMS) as the internal standard. Mass spectra were recorded using electrospray ionization (ESI) on a Shimadzu LCMS2020 spectrometer. Elemental analyses were performed on a Carlo Erba EA1106 elemental analyzer. Melting points were determined in open capillary tubes on a Stuart SMP3 melting point apparatus and are uncorrected. Microwave reactions were carried out in an Anton Paar Monowave 300 microwave instrument (850 W maximum power, 2.45 GHz). Analytical thin-layer chromatography (TLC) was performed on precoated Merck 60 F₂₅₄ silica gel plates with visualization under ultraviolet (UV) light. Substituted thiosemicarbazones 6a–h were synthesized as previously described [23–25].

Compounds 3a,b

A solution of bis-chalcone 2a or 2b (5.34 mmol) in ethyl acetate (20 mL) in a Parr hydrogenation bottle was treated with Pd/C (20%, 400 mg), and the mixture was hydrogenated under a pressure of 3 atm for 3 h at room temperature. The catalyst was removed by filtration using a celite pad. The filtrate was concentrated and the residue was purified by silica gel chromatography eluting with a gradient of 10–20% of ethyl acetate in hexanes [26].

1,1'-(4,6-Dihydroxy-1,3-phenylene)bis(3-phenylpropan-1-one) (3a) White solid; yield 95%; mp 88–90°C; IR: 3023, 1653 cm⁻¹; ¹H NMR (CDCl₃): δ 12.97 (s, 2H, OH), 8.04 (s, 1H, Ar), 7.34–7.20 (m, 10H, Ar), 6.42 (s, 1H, Ar), 3.19 (t, 4H, *J* = 7.3 Hz, CH₂), 3.04 (t, 4H, *J* = 7.3 Hz, CH₂); ¹³C NMR (CDCl₃): δ 203.5, 168.7, 140.4, 134.6, 128.7, 128.4, 126.5, 113.1, 105.1, 39.6, 30.2; MS: *m/z* 374.9 [(M + H)⁺, 100%]. Anal. Calcd for C₂₄H₂₂O₄: C, 76.99; H, 5.92. Found: C, 76.94; H, 5.89.

1,1'-(4,6-Dihydroxy-1,3-phenylene)bis(3-(4-methoxyphenyl)propan-1-one) (3b) White solid; yield 90%; mp 120–122°C; IR: 2910, 1634 cm⁻¹; ¹H NMR (CDCl₃): δ 12.98 (s, 2H, N-H), 8.07 (s, 1H, Ar), 7.13 (d, 4H, *J* = 7.1 Hz, Ar), 6.83 (d, 4H, *J* = 7.1 Hz, Ar), 6.41 (s, 1H, Ar-H), 3.77 (s, 6H, OCH₃), 3.16 (t, 4H, *J* = 7.5 Hz, CH₂), 2.98 (t, 4H, *J* = 7.5 Hz, CH₂); ¹³C NMR (CDCl₃): δ 203.6, 168.7, 158.2, 134.6, 132.4, 129.4, 114.1, 113.1, 105, 55.2, 39.9, 29.4; MS: *m/z* 435.1 [(M + H)⁺, 100%]. Anal. Calcd for C₂₆H₂₆O₆: C, 71.87; H, 6.03. Found: C, 71.82; H, 5.98.

Compounds 4a,b

A mixture of 1,1'-(4,6-dihydroxy-1,3-phenylene)bis(3-substituted propan-1-one) 3a or 3b (10 mmol), chloroacetone (22 mmol) and potassium carbonate (30 mmol) in dried acetone (10 mL) was heated under reflux for 6 h. Then the mixture was quenched with crushed ice and extracted with ethyl acetate (2 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, concentrated and purified by silica gel (60–120 mesh) column chromatography eluting with a gradient of 20–30% of ethyl acetate in hexanes.

1,1'-(3,5-Diphenethylbenzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)diethanone (4a) White solid; yield 90%; mp 138–140°C; IR: 3087, 2923, 1670, 1558 cm⁻¹; ¹H NMR (CDCl₃): δ 7.56 (s, 1H, Ar), 7.22 (m, 11H, Ar), 3.36 (t, 4H, *J* = 8 Hz, CH₂), 2.95 (t, 4H, *J* = 8 Hz, CH₂), 2.62 (s, 6H, CH₃); ¹³C NMR (CDCl₃): δ 190.8, 154.3, 148.8, 141.3, 128.6, 128.3, 127.8, 126.4, 126.2, 113.6, 94.9, 35.6, 27.8, 26.4; MS: *m/z* 451 [(M + H)⁺, 100%]. Anal. Calcd for C₃₀H₂₆O₄: C, 79.98; H, 5.82. Found: C, 79.94; H, 5.78.

1,1'-(3,5-Bis(4-methoxyphenethyl)benzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)diethanone (4b) White solid; yield 90%; mp 136–138°C; IR: 3059, 2934, 1685, 1571 cm⁻¹; ¹H NMR (CDCl₃): δ 7.56 (s, 1H, Ar), 7.25 (s, 1H, Ar), 7.12 (d, 4H, *J* = 8 Hz, Ar), 6.77 (d, 4H, *J* = 8 Hz, Ar), 3.70 (s, 6H, OCH₃), 3.33 (t, 4H, *J* = 8 Hz, CH₂), 2.89 (t, 4H, *J* = 7.7 Hz, CH₂), 2.62 (s, 6H, CH₃); ¹³C NMR (CDCl₃): δ 190.7, 158, 154.3, 148.9, 133.4, 127.9, 128, 126.5, 113.7, 113.7, 94.9, 55.1, 34.8, 27.8, 26.6; MS: *m/z* 511 [(M + H)⁺, 100%]. Anal. Calcd for C₃₂H₃₀O₆: C, 75.28; H, 5.92. Found: C, 75.23; H, 5.89.

Compounds 5a,b

Pyridinium tribromide (70 mmol) was added in portions to a stirred solution of compound **4a** or **4b** (28 mmol) in acetic acid (100 mL) at 50–55°C and stirring was continued for 4 h. Then the mixture was quenched with crushed ice and extracted with ethyl acetate (2 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, concentrated and purified by silica gel chromatography eluting with a gradient from 20% to 30% of ethyl acetate in hexanes.

1,1'-(3,5-Diphenethylbenzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-bromoethanone) (5a) Off-white solid; yield 85%; mp 138–140°C; IR: 2924, 1682, 1571, 818 cm⁻¹; ¹H NMR (CDCl₃): δ 7.59 (s, 1H, Ar), 7.22 (m, 11H, Ar), 4.53 (s, 4H, CH₂), 3.38 (t, 4H, *J* = 8 Hz, CH₂), 2.96 (t, 4H, *J* = 8 Hz, CH₂); ¹³C NMR (CDCl₃): δ 183.3, 154.8, 146.8, 141, 130.9, 128.7, 128.4, 126.5, 126.3, 114.2, 95.4, 35.6, 32.1, 26.5; MS: *m/z* 609.3 [(*M* + 2H)⁺, 100%]. Anal. Calcd for C₃₀H₂₄Br₂O₄: C, 59.23; H, 3.98. Found: C, 59.19; H, 3.94.

1,1'-(3,5-Bis(4-methoxyphenethyl)benzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-bromoethanone) (5b) Off-white solid; yield 82%; mp 134–136°C; IR: 2931, 1678, 1577, 819 cm⁻¹; ¹H NMR (CDCl₃): δ 7.59 (s, 1H, Ar), 7.27 (s, 1H, Ar), 7.10 (d, 4H, *J* = 8 Hz, Ar-H), 6.77 (d, 4H, *J* = 8 Hz, Ar), 4.53 (s, 4H, CH₂), 3.70 (s, 6H, OCH₃), 3.36 (t, 4H, *J* = 8 Hz, CH₂), 2.90 (t, 4H, *J* = 8 Hz, CH₂); ¹³C NMR (CDCl₃): δ 183.5, 158.1, 154.9, 146.7, 133.1, 131.2, 129.6, 126.5, 114.4, 113.8, 95.4, 55.2, 34.7, 32.1, 26.7; MS: *m/z* 669.2 [(*M* + 2H)⁺, 100%]. Anal. Calcd for C₃₂H₂₈Br₂O₆: C, 57.50; H, 4.22. Found: C, 57.45; H, 4.18.

General procedures for the preparation of compounds 7a–j

Conventional heating method A To a stirred solution of **5a** or **5b** (0.001 mol) in ethanol (10 mL), was added substituted thiosemicarbazone **6a–h** (0.002 mol) in ethanol (10 mL). The mixture was heated under reflux for a period of time indicated below and then concentrated under reduced pressure, and the residue was subjected to column chromatography on basic alumina eluting with a gradient from 30 to 40% of ethyl acetate in hexanes.

Microwave irradiation method B A mixture of **5a** or **5b** (0.001 mol), substituted thiosemicarbazone **6a–h** (0.002 mol) and ethanol (10 mL) in a microwave tube was subjected to microwave irradiation at 180 W for 8–20 min. Work-up and purification were conducted as described above.

4,4'-(3,5-Diphenethylbenzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)bis(2-(2-benzylidenehydrazino)thiazole) (7a) Reaction time 8 h, yield 85%, method A; reaction time 10 min, yield 92%, method B; off-white solid; mp 170–172°C (dec); IR: 3464, 1563, 1491, 1359, 753 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 12.16 (s, 2H, NH), 8.13 (s, 2H, CH=N), 7.71 (s, 1H, Ar), 7.69 (d, 4H, *J* = 7 Hz, Ar), 7.40 (m, 11H, Ar), 7.27 (m, 6H, Ar, thiazole), 7.17 (t, 2H, *J* = 7 Hz, Ar), 3.47 (t, 4H, *J* = 7 Hz, CH₂), 2.98 (t, 4H, *J* = 7 Hz, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.7, 151.8, 146.8, 142.9, 142.5, 141.7, 134.3, 129.3, 128.8, 128.6, 128.1, 127.6, 126.3, 125.8, 115.6, 109.3, 106, 93.5, 35.5, 25.1; MS: *m/z* 769.1 [(*M* + H)⁺, 100%]. Anal. Calcd for C₄₆H₃₆N₆O₂S₂: C, 71.85; H, 4.72; N, 10.93. Found: C, 71.80; H, 4.69; N, 10.94.

4,4'-(3,5-Bis(4-methoxyphenethyl)benzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(2-benzylidenehydrazino)thiazole) (7b) Reaction time 10 h, yield 80%, method A; reaction time 15 min, yield 86%; method B; off-white solid; mp 114–116°C (dec); IR: 3463, 1564, 1509, 1364, 754 cm⁻¹; ¹H NMR (DMSO-*d*₆ + D₂O): δ 8.12 (s, 2H, CH=N), 7.68 (d, 4H, *J* = 7 Hz, Ar), 7.55 (s, 1H, Ar), 7.52–7.36 (m, 7H, Ar), 7.18 (s, 2H, thiazole), 7.14 (d, 4H, *J* = 8 Hz, Ar), 6.77 (d, 4H, *J* = 8 Hz, Ar), 3.61 (s, 6H, OCH₃), 3.44–3.25 (m, 4H, CH₂), 2.87 (t, 4H, *J* = 7 Hz, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.6, 157.4, 151.8, 146.8, 142.9, 141.6, 134.3, 133.6, 129.6, 129.3, 128.8, 128.6, 126.3, 115.6, 113.5, 109.4, 106, 93.4, 54.8, 34.7, 25.5; MS: *m/z* 829.2 [(*M* + H)⁺, 100%]. Anal. Calcd for C₄₈H₄₀N₆O₄S₂: C, 69.54; H, 4.86; N, 10.14. Found: C, 69.50; H, 4.81; N, 10.15.

4,4'-(3,5-Bis(phenethyl)benzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(3-hydroxybenzylidene)hydrazino)thiazole) (7c) Reaction time 12 h, yield 75%, method A; reaction time 20 min, yield 86%, method B; off-white solid; mp 138–140°C (dec); IR: 3463, 1560, 1491, 1364, 748 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 12.09 (s, 2H, N-H), 9.66 (s, 2H, OH), 8.03 (s, 2H, CH=N), 7.71 (s, 1H, Ar), 7.43 (s, 1H, Ar), 7.41–7.04 (m, 18H, Ar, thiazole), 6.80 (d, 2H, *J* = 7 Hz, Ar), 3.49 (m, 4H, CH₂), 2.94 (m, 4H, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.7, 157.6, 151.9, 146.9, 142.9, 142, 141.7, 135.6, 129.9, 128.7, 128.2, 126.3, 125.9, 118, 116.8, 115.6, 112.1, 109.3, 106.1, 93.5, 35.6, 25.2; MS: *m/z* 801.3 [(*M* + H)⁺, 100%]. Anal. Calcd for C₄₆H₃₆N₆O₄S₂: C, 68.98; H, 4.53; N, 10.49. Found: C, 68.93; H, 4.49; N, 10.50.

4,4'-(3,5-Bis(4-methoxyphenethyl)benzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(2-(3-hydroxybenzylidene)hydrazino)thiazole) (7d) Reaction time 16 h, yield 70%, method A; reaction time 20 min, yield 85%; method B; brown solid; mp 124–126°C (dec); IR: 3465, 1562, 1508, 1365, 730 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 12.09 (s, 2H, N-H), 9.65 (s, 2H, O-H), 8.03 (s, 2H, CH=N), 7.70 (s, 1H, Ar), 7.33 (s, 1H, Ar), 7.29–7.19 (m, 8H, Ar, thiazole), 7.13 (s, 2H, Ar), 7.06 (d, 2H, *J* = 7 Hz, Ar), 6.81 (m, 6H, Ar), 3.66 (s, 6H, OCH₃), 3.53 (m, 4H, CH₂), 2.91 (t, 4H, *J* = 7 Hz, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.7, 157.6, 157.5, 151.8, 146.8, 142.9, 141.9, 135.6, 133.6, 129.9, 129.6, 126.4, 118, 116.8, 115.7, 113.5, 112.1, 109.4, 106, 93.5, 54.9, 34.7, 25.5; MS: *m/z* 861.2 [(*M* + H)⁺, 100%]. Anal. Calcd for C₄₈H₄₀N₆O₆S₂: C, 66.96; H, 4.68; N, 9.76. Found: C, 66.91; H, 4.63; N, 9.78.

4,4'-(3,5-Diphenethylbenzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(2-(4-methoxybenzylidene)hydrazino)thiazole) (7e) Reaction time 12 h, yield 85%, method A; reaction time 8 min, yield 91%, method B; off-white solid; mp 112–114°C (dec); IR: 3465, 1557, 1506, 1362, 742 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 11.99 (s, 2H, N-H), 8.07 (s, 2H, CH=N), 7.69 (s, 1H, Ar), 7.62 (d, 4H, *J* = 8 Hz, Ar), 7.43 (s, 1H, Ar), 7.36 (d, 4H, *J* = 7 Hz, Ar), 7.29 (m, 4H, Ar, thiazole), 7.18 (d, 4H, *J* = 7 Hz, Ar), 7.01 (d, *J* = 8 Hz, 4H, Ar), 3.80 (s, 6H, OCH₃), 3.55–3.44 (m, 4H, CH₂), 3.04–2.89 (m, 4H, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.8, 160.2, 151.8, 146.9, 142.9, 141.7, 141.2, 128.6, 128.1, 127.8, 126.9, 126.3, 125.8, 115.5, 114.3, 109.2, 105.7, 93.4, 55.2, 35.5, 25.1; MS: *m/z* 829.2 [(*M* + H)⁺, 100%]. Anal. Calcd for C₄₈H₄₀N₆O₄S₂: C, 69.54; H, 4.86; N, 10.14. Found: C, 69.50; H, 4.81; N, 10.16.

4,4'-(3,5-Bis(4-methoxyphenethyl)benzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(2-(4-methoxybenzylidene)hydrazino)thiazole) (7f) Reaction time 15 h, yield 72%, method A; reaction time 15 min, yield 86%, method B; off-white solid; mp 110–112°C (dec); IR: 3465, 1562, 1508, 1364, 731 cm⁻¹; ¹H NMR (DMSO-*d*₆ + D₂O): δ 8.02 (s, 2H,

CH=N), 7.63 (s, 1H, Ar), 7.57 (d, 4H, $J=8$ Hz, Ar), 7.28 (s, 1H, Ar), 7.19 (d, 4H, $J=7$ Hz, Ar), 7.12 (s, 2H, thiazole), 6.96 (d, 4H, $J=8$ Hz, Ar), 6.75 (d, 4H, $J=7$ Hz, Ar), 3.78 (s, 6H, OCH₃), 3.60 (s, 6H, OCH₃), 3.47–3.21 (m, 4H, CH₂), 2.88 (m, 4H, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.7, 160.2, 157.4, 151.8, 146.8, 142.9, 141.7, 133.6, 129.6, 127.8, 126.9, 126.3, 115.6, 114.3, 113.5, 109.3, 105.6, 93.4, 55.2, 54.8, 34.7, 25.5; MS: m/z 889.2 [(M+H)⁺, 100%]. Anal. Calcd for C₅₀H₄₄N₆O₆S₂: C, 67.55; H, 4.99; N, 9.45. Found: C, 67.50; H, 4.94; N, 9.47.

4,4'-(3,5-Diphenethylbenzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(2-bromobenzylidene)hydrazino)thiazole (7g) Reaction time 10 h, yield 75%, method A; reaction time 10 min, yield 89%, method B; brown solid; mp 206–208°C (dec); IR: 3463, 1560, 1508, 1348, 752 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 12.40 (s, 2H, N-H), 8.46 (s, 2H, CH=N), 8.02–7.86 (m, 2H, Ar), 7.84 (s, 1H, Ar), 7.68 (d, 2H, $J=7.5$ Hz, Ar), 7.52–7.19 (m, 17H, Ar-H, thiazole), 3.47 (t, $J=7$ Hz, 4H, CH₂), 2.98 (t, $J=7$ Hz, 4H, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.4, 152.1, 146.8, 142.4, 141.6, 139.8, 133.1, 133, 130.9, 128.5, 128.3, 128.1, 126.5, 125.8, 124.6, 122.7, 116.1, 109.2, 106.3, 93.7, 35.5, 25.6; MS: m/z 927.3 (M⁺, 100%). Anal. Calcd for C₄₆H₃₄Br₂N₆O₂S₂: C, 59.62; H, 3.70; N, 9.07. Found: C, 59.58; H, 3.65; N, 9.10.

4,4'-(3,5-Diphenethylbenzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(2-(3-bromobenzylidene)hydrazino)thiazole) (7h) Reaction time 10 h, yield 78%, method A; reaction time 10 min, yield 87%, method B; brown solid; mp 216–218°C (dec); IR: 3463, 1558, 1479, 1359, 739 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 12.31 (s, 2H, N-H), 8.08 (s, 2H, CH=N), 7.86 (s, 2H, Ar), 7.71 (s, 1H, Ar), 7.68 (d, 2H, $J=8$ Hz, Ar), 7.58 (d, 2H, $J=8$ Hz, Ar), 7.45 (s, 1H, Ar), 7.42 (d, 2H, $J=8$ Hz, Ar), 7.41–7.24 (m, 10H, Ar, thiazole), 7.17 (t, 2H, $J=8$ Hz, Ar), 3.47 (t, 4H, $J=8$ Hz, CH₂), 2.98 (t, 4H, $J=8$ Hz, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.5, 151.8, 146.8, 142.9, 141.6, 139.8, 136.8, 131.8, 131, 128.6, 128.4, 128.1, 126.3, 125.8, 125.2, 122.2, 115.6, 109.3, 106.3, 93.5, 35.5, 25.1; MS: m/z 926.9 (M⁺, 100%). Anal. Calcd for C₄₆H₃₄Br₂N₆O₂S₂: C, 59.62; H, 3.70; N, 9.07. Found: C, 59.57; H, 3.66; N, 9.09.

4,4'-(3,5-Bis(4-methoxyphenethyl)benzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(2-(3-bromobenzylidene)hydrazino)thiazole) (7i) Reaction time 12 h, yield 75%, method A; reaction time 10 min, yield 86%, method B; brown solid; mp 118–120°C (dec); IR: 3462, 1565, 1511, 1366, 735 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 12.31 (s, 2H, N-H), 8.09 (s, 2H, CH=N), 7.86 (s, 2H, Ar), 7.70 (m, 3H, Ar), 7.58 (d, 2H, $J=8$ Hz, Ar), 7.41 (t, 2H, $J=8$ Hz, Ar), 7.34 (s, 1H, Ar), 7.25 (m, 6H, Ar, thiazole), 6.82 (d, 4H, $J=8$ Hz, Ar), 3.66 (s, 6H, OCH₃), 3.41 (m, 4H, CH₂), 2.91 (t, 4H, $J=7$ Hz, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.4, 157.4, 151.8, 146.7, 143, 139.7, 136.8, 133.6, 131.7, 130.9, 129.6, 128.4, 126.3, 125.2, 122.2, 115.7, 113.5, 109.4, 106.2, 93.4, 54.8, 34.7, 25.5; MS: m/z 986.79 (M⁺, 100%). Anal. Calcd for C₄₈H₃₈Br₂N₆O₄S₂: C, 58.42; H, 3.88; N, 8.52. Found: C, 58.38; H, 3.84; N, 8.54.

4,4'-(3,5-Diphenethylbenzo[1,2-*b*:5,4-*b'*]difuran-2,6-diyl)-bis(2-(2-(2-chlorobenzylidene)hydrazino)thiazole) (7j) Reaction time 8 h; off-white solid; yield 70%, method A; reaction time 10 min, yield 86%, method B; mp 150–152°C (dec); IR: 3463, 1559, 1508, 1362, 748 cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 12.40 (s, 2H, N-H), 8.49 (s, 2H, CH=N), 7.95 (dd, 2H, $J=2.2$, 6.7 Hz, Ar), 7.70 (s, 1H, Ar), 7.52 (dd, 2H, $J=2.2$, 6.7 Hz, Ar), 7.48–7.40 (m, 5H, Ar), 7.36 (d, 4H, $J=7.1$ Hz, Ar), 7.29 (d, 4H, $J=7.1$ Hz, Ar), 7.25 (s, 2H, thiazole), 7.17 (t, 2H, $J=7.1$ Hz, Ar), 3.46 (t, 4H, $J=7.3$ Hz, CH₂), 2.98 (t, 4H, $J=7.3$ Hz, CH₂); ¹³C NMR (DMSO-*d*₆): δ 168.3, 151.8, 146.7, 143, 141.7, 141.2, 137.4, 132.2, 131.5, 130.6, 129.9, 128.6, 128.1, 127.6, 126.1, 125.8, 115.7, 109.2, 106.3, 93.5, 35.5, 25.2; MS: m/z

837.5 (M⁺, 100%). Anal. Calcd for C₄₆H₃₄Cl₂N₆O₂S₂: C, 65.94; H, 4.09; N, 10.03. Found: C, 65.90; H, 4.04; N, 10.05.

Antibacterial assay

Gram-negative strains (*P. aeruginosa* and *E. coli*) and Gram-positive strains (*B. subtilis* and *S. aureus*) were obtained from the Microbial Type Culture Collection. The biological activities were assayed using the standard disc diffusion method [27] for 100 µg/mL solutions in DMSO. Inhibition zones were measured, compared with the standard positive control of norfloxacin (+ve stains) and ofloxacin (–ve stains) at 100 µg/mL.

Antimycobacterial assay

Isolated single colonies of *Mycobacterium bovis*, 7H10 agar plate and Middlebrook 7H9 medium were used. The activity was assayed by the turbidometry method [28] using a mixture of isoniazid and rifampicin as standard.

Acknowledgments: The authors are grateful to the Head, Department of Chemistry, Osmania University, Hyderabad and ICT, Hyderabad for providing analytical and biological facilities. The authors are thankful to Chemveda Life Sciences Pvt. Ltd., IDA, Uppal, Hyderabad, for providing laboratory facilities. Ananda Rao thanks CSIR, New Delhi, India for a research fellowship.

References

- [1] Ghasemi, B.; GhasemSanjarani, G.; Sanjarani, Z.; Majidiani, H. Evaluation of anti-bacterial effects of some novel thiazole and imidazole derivatives against some pathogenic bacteria. *Iran J. Microbiol.* **2015**, *7*, 281–286.
- [2] Zhou, X.; Shao, L.; Jin, Z.; Liu, J. B.; Dai, H.; Fang, J. X. Synthesis and antitumor activity evaluation of some schiff bases derived from 2-aminothiazole derivatives. *Heteroatom Chem.* **2007**, *18*, 55–59.
- [3] Kucukguzel, G.; Kocatepe, A.; De-Clercq, E.; Sahin, F.; Gulluce, M. Synthesis and biological activity of 4-thiazolidinones, thio-semicarbazides derived from diflunisal hydrazide. *Eur. J. Med. Chem.* **2006**, *41*, 353–359.
- [4] Vicini, P.; Geroniki, A.; Anastasia, K.; Incerti, M.; Zani, F. Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. *Bioorg. Med. Chem.* **2006**, *14*, 3859–3864.
- [5] Bell, F. W.; Cantrell, A. S.; Hoegberg, M.; Jaskunas, S. R.; Johansson, N. G.; Jordon, C. L.; Kinnick, M. D.; Lind, P.; Morin, J. M.; Noreen, R. Jr. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. *J. Med. Chem.* **1995**, *38*, 4929–4936.

- [6] Patt, W. C.; Hamilton, H. W.; Taylor, M. D.; Ryan, M. J.; Taylor, D. G.; Connolly, C. J.; Doherty, A. M.; Klutchko, S. R.; Sircar, I. Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. *J. Med. Chem.* **1992**, *14*, 2562–2572.
- [7] Sharma, P. K.; Sawhney, S. N. Potent antiinflammatory 3-thiazole-4(5)-acetic acids of 1,2-benzisothiazole. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 2427–2430.
- [8] Vicini, P.; Geronikakib, A.; Incertia, M.; Busonerac, B.; Ponc, G.; Cabrasc, C. A.; Collac, P. L. Synthesis and biological evaluation of benzo[d]isothiazole, benzothiazole and thiazole Schiff bases. *Bioorg. Med. Chem.* **2003**, *11*, 4785–4789.
- [9] Sharma, S. K.; Tandon, M.; Lown, J. W. Design and synthesis of novel thiazole-containing cross-linked polyamides related to the antiviral antibiotic distamycin. *J. Org. Chem.* **2000**, *65*, 1102–1107.
- [10] Lu, Y.; Li, C. M.; Wang, Z.; Ross, C. R.; Chen, J.; Dalton, J. T.; Li, W.; Miller, D. D. Discovery of 4-substituted methoxybenzoyl-aryl-thiazoles as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. *J. Med. Chem.* **2009**, *52*, 1701–1711.
- [11] Narang, R.; Narasimhan, B.; Sharma, S. A review on biological activities and chemical synthesis of hydrazide derivatives. *Curr. Med. Chem.* **2012**, *19*, 569–612.
- [12] Kalinowski, D. S.; Quach, P.; Richardson, D. R. Thiosemicarbazones: the new wave in cancer treatment. *Future Med. Chem.* **2009**, *6*, 1143–1151.
- [13] Braga, P. F. S.; Fonseca, C. N.; Ramos, P. J.; Souza-Fagundes, D. M. E.; Oliveira, D. B. R. Synthesis and cytotoxicity evaluation of thiosemicarbazones and their thiazole derivatives. *Braz. J. Pharm. Sci.* **2016**, *52*, 299–307.
- [14] Lv, P. C.; Wang, K. R.; Yang, Y.; Mao, W. J.; Chen, J.; Xiong, J.; Zhu, H. L. Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 6750–6754.
- [15] Abhale, Y. K.; Deshmukh, K. K.; Shinde, A.; Mhaske, P. C.; Nawale, L.; Sarkar, D. Synthesis, antitubercular and antimicrobial potential of some new thiazole substituted thiosemicarbazide derivatives. *Med. Chem. Res.* **2017**, *26*, 2557–2567.
- [16] Gammill, R. B.; Hyde, B. R. Total synthesis of the lipid-altering and antiatherosclerotic furochromonekhellin. The furoic acid route to highly functionalized benzofurans. *J. Org. Chem.* **1983**, *48*, 3863–3865.
- [17] Kim, S.; Salim, A. A.; Swanson, S. M.; Kinghorn, A. D. Potential of cyclopenta[b]benzofurans from aglaia species in cancer chemotherapy. Advanced anticancer agents. *Med. Chem.* **2006**, *6*, 319–345.
- [18] Rida, S. M.; El-Hawash, S. A.; Fahmy, H. T.; Hazza, A. A.; El-Meligy, M. M. Synthesis and *in vitro* evaluation of some novel benzofuran derivatives as potential anti-HIV-1, anticancer and antimicrobial agents. *Arch. Pharm. Res.* **2006**, *29*, 16–25.
- [19] Lavanya, A.; Sribalan, R.; Padmini, V. Synthesis and biological evaluation of new benzofuran carboxamide derivatives. *J. Saudi Chem. Soc.* **2015**, *21*, 277–285.
- [20] Frecentese, F.; Saccone, I.; Caliendo, G.; Corvino, A.; Fiorino, F.; Magli, E.; Perissutti, E.; Severino, B.; Santagada, V. Microwave assisted organic synthesis of heterocycles in aqueous media: recent advances in medicinal chemistry. *Med. Chem.* **2016**, *12*, 720–732.
- [21] Baba, K. H. N.; Ashok, D.; Rao, A. B.; Sarasija, M.; Murthy, S. Y. N.; Rao, S. V.; Parthasarathy, T. Microwave-assisted synthesis of bis(*N*-substituted thiazol-2-amine) derivatives and their biological activities. *Heterocycl. Commun.* **2017**, *23*, 405–409.
- [22] Song, J.; Zhao, H.; Liu, Y.; Han, H.; Li, Z.; Chu, W.; Sun, Z. Efficient symmetrical bidentate dioxime ligand-accelerated homogeneous palladium-catalyzed Suzuki–Miyaura coupling reactions of aryl chlorides. *New J. Chem.* **2017**, *41*, 372–376.
- [23] Yi, W.; Cao, R. H.; Chen, Y. Z.; Yu, L.; Ma, L.; Song, C. H. Design, synthesis and biological evaluation of hydroxy- or methoxy-substituted phenylmethylenethiosemicarbazones as tyrosinase inhibitors. *Chem. Pharm. Bull.* **2009**, *57*, 1273–1277.
- [24] Raymond, F. H.; Kpoviessi, S.; Gbaguidi, F.; Bero, J.; Hannaert, V.; Quetin-Leclercq, J.; Poupaert, J.; Moudachirou, M.; Accrombessi, C. G. Structure-activity relationship study of thiosemicarbazones on an African trypanosome: *Trypanosoma brucei*. *Med. Chem. Res.* **2013**, *22*, 2151–2162.
- [25] Chuljin, A.; Hemant, H.; Nitinkumar, S. S. Synthesis of some novel thiazolyl-azetidinone hybrids. *J. Korean Chem. Soc.* **2016**, *60*, 107–110.
- [26] Reddy, V. V. K.; Anuradha, P.; Ashok, D. A facile synthesis of 4,6-bis(3'-arylpropanoyl) resorcinols and their antifeedant activity. *Indian J. Heterocycl. Chem.* **2000**, *9*, 169–172.
- [27] Cleidson, V.; Simone, M. de S.; Elza, F. A. S.; Artur, S. Jr. Screening methods to determine antibacterial activity of natural products. *Braz. J. Microbiol.* **2007**, *38*, 369–380.
- [28] Sudha, S. K.; Sri, S. A. N.; Lavanya, N.; Tanmay, B.; Haridas, B. R.; Prathama, S. M.; Ramesh, U. Identification of new molecular entities (NMEs) as potential leads against tuberculosis from open source compound repository. *PLoS One* **2015**, *10*, e0144018.